Baker Bros. Advisors’s Tango Therapeutics TNGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.32M Hold
333,333
– – 0.04% 68
2026
Q2
$10.4M Buy
+333,333
New +$8.24M 0.05% 68
2024
Q4
– Sell
-750,000
Closed -$5.78M – 102
2024
Q3
$5.78M Hold
750,000
– – 0.06% 63
2024
Q2
$6.44M Hold
750,000
– – 0.08% 57
2024
Q1
$5.96M Hold
750,000
– – 0.07% 60
2023
Q4
$7.42M Hold
750,000
– – 0.08% 57
2023
Q3
$8.44M Hold
750,000
– – 0.05% 49
2023
Q2
$2.49M Hold
750,000
– – 0.01% 89
2023
Q1
$2.96M Hold
750,000
– – 0.02% 82
2022
Q4
$5.44M Hold
750,000
– – 0.03% 77
2022
Q3
$2.72M Hold
750,000
– – 0.02% 95
2022
Q2
$3.4M Hold
750,000
– – 0.02% 87
2022
Q1
$5.68M Hold
750,000
– – 0.03% 82
2021
Q4
$8.2M Hold
750,000
– – 0.04% 81
2021
Q3
$9.7M Buy
+750,000
New +$8.99M 0.04% 78

Other funds holding TNGX

Baker Bros. Advisors's TNGX Position: Q3 2026 in Review

Baker Bros. Advisors held its Tango Therapeutics (TNGX) position steady in Q3 2026 at 333,333 shares worth $8.32M. The position accounts for 0.04% of the portfolio, ranked #68.

Baker Bros. Advisors first reported a position in TNGX in Q3 2021 and has held it in 15 quarters since. The position peaked at $10.4M in Q2 2026. 257 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.

  • Baker Bros. Advisors held 333,333 shares of Tango Therapeutics worth $8.32M as of Q3 2026.
  • Baker Bros. Advisors left its Tango Therapeutics share count unchanged in Q3 2026.
  • Tango Therapeutics made up 0.04% of Baker Bros. Advisors's portfolio in Q3 2026, its #68 holding.
  • Baker Bros. Advisors first reported a position in Tango Therapeutics in Q3 2021 and has held it in 15 quarters since.
  • Baker Bros. Advisors's Tango Therapeutics position peaked at $10.4M in Q2 2026.
  • 257 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.

Based on Baker Bros. Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.